BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. The company has collaboration with Orbit Biomedical, Ltd. BioTime, Inc. was founded in 1990 and is based in Alameda, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
Phone+1-510-5213390
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees92
Next Earnings Date3/21/2019 (Estimated)
OptionableOptionable
BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions
What is BioTime's stock symbol?
BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."
How were BioTime's earnings last quarter?
BioTime, Inc. (NYSEAMERICAN:BTX) issued its quarterly earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.06. The biotechnology company earned $1.27 million during the quarter, compared to the consensus estimate of $1.75 million. View BioTime's Earnings History.
When is BioTime's next earnings date?
What price target have analysts set for BTX?
5 brokerages have issued twelve-month target prices for BioTime's shares. Their forecasts range from $3.00 to $4.00. On average, they expect BioTime's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 173.4% from the stock's current price. View Analyst Price Targets for BioTime.
What is the consensus analysts' recommendation for BioTime?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTime.
What are Wall Street analysts saying about BioTime stock?
Here are some recent quotes from research analysts about BioTime stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We are instituting a Buy rating and $4 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities for OpRegen (approximately 57% valuation contribution) on only the U.S. opportunity and Revevia (43% valuation contribution) in the E.U. We note that our current projected values for both these assets are based on minimal market penetration in very large markets." (2/21/2019)
- 2. Maxim Group analysts commented, "BioTime announced that its affiliate, OncoCyte (OCX – NR, BTX has 36% stake), reported positive results from an R&D validation study of DetermaVu, a non- invasive, liquid biopsy test for the early diagnosis of lung cancer. On this news, BioTime shares on 1/29 were up ~50%, OncoCyte shares were up over 200%, and even Asterias (AST – NR) shares, a cell therapy company soon to be fully acquired by BioTime, were up ~45%." (1/30/2019)
- 3. According to Zacks Investment Research, "BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime's research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. " (1/8/2019)
Has BioTime been receiving favorable news coverage?
Media coverage about BTX stock has been trending positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioTime earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Are investors shorting BioTime?
BioTime saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 9,909,836 shares, a decrease of 11.3% from the January 15th total of 11,173,119 shares. Based on an average daily volume of 1,959,934 shares, the short-interest ratio is presently 5.1 days. Currently, 8.2% of the shares of the stock are sold short. View BioTime's Current Options Chain.
Who are some of BioTime's key competitors?
Some companies that are related to BioTime include Mesoblast (MSB), Theratechnologies (TH), Emerald Health Therapeutics (EMH), Senesco Technologies (ELOX), Starpharma (SPL), Neptune Wellness Solutions (NEPT), 22nd Century Group (XXII), IMV (IMV), Enochian Biosciences (ENOB), Kodiak Sciences (KOD), IMV (IMV), Monash IVF Group (MVF), ProMetic Life Sciences (PLI), OncoCyte (OCX) and Emblem (EMC).
What other stocks do shareholders of BioTime own?
Who are BioTime's key executives?
BioTime's management team includes the folowing people:
- Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)
- Mr. Russell L. Skibsted, Chief Financial Officer (Age 60)
- Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 65)
- Mr. Brian M. Culley, CEO , Pres & Director (Age 48)
- Ms. Brandi L. Roberts, CFO & Sr. VP of Fin. (Age 45)
Who are BioTime's major shareholders?
BioTime's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.87%), Defender Capital LLC. (3.14%), Geode Capital Management LLC (0.97%), IndexIQ Advisors LLC (0.62%), Two Sigma Investments LP (0.42%) and Bank of New York Mellon Corp (0.32%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime.
Which institutional investors are selling BioTime stock?
BTX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, IndexIQ Advisors LLC and Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for BioTime.
Which institutional investors are buying BioTime stock?
BTX stock was acquired by a variety of institutional investors in the last quarter, including Defender Capital LLC., Two Sigma Investments LP, BlackRock Inc., Two Sigma Advisers LP, Jane Street Group LLC, LPL Financial LLC, Rhumbline Advisers and Geode Capital Management LLC. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime.
How do I buy shares of BioTime?
Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioTime's stock price today?
One share of BTX stock can currently be purchased for approximately $1.28.
How big of a company is BioTime?
BioTime has a market capitalization of $162.51 million. BioTime employs 92 workers across the globe.
What is BioTime's official website?
How can I contact BioTime?
BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.
MarketBeat Community Rating for BioTime (NYSEAMERICAN BTX)
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
